Cephalon has announced positive results from a Phase IV trial of Nuvigil (armodafinil) tablets for excessive sleepiness associated with shift work disorder.
The six-week, double-blind and placebo-controlled study included 383 patients.
Patients treated with Nuvigil showed an improvement in their condition as well as a reduction in impairment, when compared to a placebo.
The drug also improved Global Assessment of Functioning score.
The adverse affects observed with the use of Nuvigil include headache, nausea, dizziness and insomnia.